Loading…
KLRS
Kalaris Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 482929106
$4.03-1.71%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $95.93M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.84
- ROE
- -79.91%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $11.88
- 52-week low
- $3.03
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.5% over 5Y.
today you would have $5.07▼ -99.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $8.44 | $9.66 | $15.64 | $117.99 | $297.62 | $884.12 | |
| P/B | 3.1x | 2.5x | — | — | 2.1x | 3.8x | 7.1x |
| EPS | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | -$59.57 | |
| ROE | -65.13% | -55.11% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DHDefinitive Healthcare Corp. | $0.89 | — | 0.7x | — | -78.37% | $95M |
| CGTXCognition Therapeutics Inc | $1.02 | — | 2.9x | — | -83.76% | $97M |
| PTHSPelthos Therapeutics Inc. | $24.73 | — | — | — | — | $94.68M |
| VRCAVerrica Pharmaceuticals Inc. | $5.69 |
About the company
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
- 20
- Berkeley Heights, United States
Company description provided by Yahoo Finance.